- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00260884
Phase III Study OF the Gastric Surgery on Advanced Stage Gastric Cancer
Phase III Study of the Effect of Radical Gastric Surgery Versus Conventional Surgery on Recurrence and Survival in Patients With Advanced Stage Gastric Cancer.
- OBJECTIVES To determine in a prospective randomized clinical trial, the effect of extended lymph node dissection (R3 gastrectomy) versus conventional surgery (R0/1 gastrectomy) on tumor recurrence and survival in Chinese patients with advanced cancer of the stomach (adenocarcinoma invasion beyond submucosa).
- STATISTICAL CONSIDERATIONS The major end points are disease free survival and survival. The log-rank test will be used as analytic method on disease-free survival and overall durvival. The follow-up time after treatment is five years.
Previous experience provides an estimation of a 20% 5-year survival rate with conventional surgery for gastric cancer. Assuming that this new treatment (radical surgery) may increase the 5-year survival rate to 40%, we estimate that 118 evaluable patients are required to detected a significance at a of 0.05 level and power of 0.8 using a one tailed test.
We expect to enter 50 patients per year and finish accrual of patient within 2.5 years.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
* TREATMENT PLAN
Patients are randomized intraoperatively into arm I (conventional [R0/R1] gastrectomy) or arm II (extended radical [R3] lymph node dissection).
Arm I: Resection of stomach, greater omentum, lesser omentum, and adjacent organ(s) when the primary tumor invaded directly. A total or distal subtotal gastrectomy is decided by the proximal distance from cardia to the tumor. A margin of 3 cm was required for well-defined (Borrmann I or II) tumors, and of 5 cm for ill-defined (Borrmann III or IV) tumors. When a total gastrectomy is performed, the distal pancreas and spleen should be preserved unless there is direct invasion into these organs. The left gastric artery should not be ligated at its origin but distal to its bifurcation into ascending and descending branches.
Arm II: The procedure are the same as in Arm I, additionally, extended lymph node dissection includes dissection of the N1, N2 and N3 nodes. These groups (N) are comprised of lymph node stations which depended on the location of the primary tumors (Fig. 1).
- For N2 dissection, the left gastric artery is ligated at its origin to facilitate the dissection of No.7. If a total gastrectomy is indicated, a splenectomy is essential for the dissection of station No. 10, and a distal pancreatectomy for the dissection of station No.11. Combined resection of these adjacent organs is not performed during a distal subtotal gastrectomy.
- If the primary cancer is located at the middle or lower third of stomach, No.1 (nodes at right cardiac) and 11 (nodes along the splenic artery) are excised routinely for frozen section before gastric resection. If no cancer metastasis is seen in both No.1 and 11 lymph nodes is performed. If only No. 1 lymph nodes is positive for cancer metastasis, total gastrectomy is performed instead of distal subtotal resection. If No. 11 lymph nodes are positive, splenectomy and distal pancreatectomy are performed in addition to the radical resection of the stomach and lymph nodes.
- For N3 dissection: No. 12 (nodes in the hepatoduodenal ligament), No. 13 (nodes at retropancreatic region) and No. 14 (nodes at the root of mesentery) are dissected.
For patients who had gastric cancer recurrence after gastrectomy, chemotherapy with cisplatin、 5-FU、Leucovorin will be given.
Cisplatin 20mg/m2 5-FU 450 mg/m2 Leucovorin 90 mg/m2
The above three drugs to be given in 500ml of normal saline and infused intravenously simultaneously over 96 hours and repeated every 3 weeks. (21days)
Dose modification: Delay treatment for one week (if WBC<4000/dl immediately before treatment). Reduce dose of subsequent cycles of 5-FU by 20% if WBC nadir <1000/dl.
Delay treatment for one week (if there is oral mucositis or diarrhea immediately before treatment). Reduce dose of subsequent cycles of 5-FU by 10% for grade 2 and 20% for grade 3 or 4 mucositis or diarrhea.
Stop treatment for any grade 4 non-hematological toxicity. Stop cisplatin treatment if serum creatinine > 2mg/dl.
Duration of treatment: Continue treatment for patients until disease progression.
* DATA AND PROTOCOL MANAGEMENT 10.1 Registration, randomization will be performed by the Cancer Clinical Trial Operations Office by calling 789-9046. (47)& 7852459.
Quality control of the data will be performed by the Cancer Clinical Trial Operations Office, Institute of Biomedical Sciences, Academia Sinica.
Data will be evaluated by the statistician and the study chairman before data analyzed
10.2 Protocol Compliance: the attending physician and oncology research nurse must see each patient prior to treatment and at follow up to ensure all investigations, treatment procedures and data records are done and recorded according to protocol.
Study Type
Enrollment
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with histologically proven adenocarcinoma of the stomach.
- No clinical early stage stomach cancer (mucosa or submucosal invasion only).
- No esophageal invasion.
- No distant metastatic disease.
- No para-aortic, macrolymphadenopathy
- No N3, macrolymphadenopathy
- Suitable for gastric surgery with curative intent.
- Medically fit for surgery.
- No emergency resection required.
- No previous gastrectomy.
- Not older than 75 years.
- Signed informed consent form.
- No previous or concomitant other cancer.
Exclusion Criteria:
- Patients is not adenocarcinoma of the stomach.
- distant metastatic disease.
- previous gastrectomy.
- older than 75 years.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
We expect to enter 50 patients per year and finish accrual of patient within 2.5 years.
|
Collaborators and Investigators
Investigators
- Study Chair: Chew-Wun Wu, Ph.D., Taipei Veterans General Hospital, Taiwan
- Principal Investigator: Su-Shun Lo, M.D., Taipei Veterans General Hospital, Taiwan
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- A1293
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Cancer
-
City of Hope Medical CenterRecruitingGastric Cancer | Gastric Adenocarcinoma | Gastric Cancer Stage IV | Gastric Neoplasm | Gastric Cancer Metastatic to Lung | Gastric Cancer Stage | Gastric Cancer Metastatic to Liver | Gastric Cancer Stage III | Gastric Cancer Stage II | Gastric Lesion | Gastric Cancer in Situ | Gastric Cancer Stage IIIB | Gastric... and other conditionsUnited States, Japan
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Pathologic Stage... and other conditionsUnited States
-
City of Hope Medical CenterActive, not recruitingAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Pathologic Stage IB Gastric Cancer AJCC v8 | Pathologic Stage II Gastric Cancer AJCC v8 | Pathologic... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedGastric Adenocarcinoma | Stage IV Gastric Cancer | Stage II Gastric Cancer | Stage III Gastric CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedGastroesophageal Junction Adenocarcinoma | Gastric Cardia Adenocarcinoma | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage IIIB Gastric Cancer AJCC v7United States
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric CancerUnited States
-
National Cancer Institute (NCI)CompletedGastric Cancer | Gastric NeoplasmsUnited States
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedGastric Cancer | Esophageal Cancer | Adenocarcinoma Gastric | Metastatic Gastric Cancer | GastroEsophageal Cancer | HER2 Positive Gastric CancerGermany
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)RecruitingGastric Adenocarcinoma | Epstein-Barr Virus Positive | Mismatch Repair Protein Deficiency | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage III Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage... and other conditionsUnited States
Clinical Trials on conventional gastrectomy or radical lymph node dissection
-
Yonsei UniversityRecruitingGastric CancerKorea, Republic of
-
Peking UniversityThe First Affiliated Hospital with Nanjing Medical University; Zhejiang Cancer... and other collaboratorsRecruiting
-
Eastern Hepatobiliary Surgery HospitalUnknownIntrahepatic CholangiocarcinomaChina
-
Sohag UniversityNot yet recruiting
-
Canadian Cancer Trials GroupCanadian Institutes of Health Research (CIHR); Institute of Cancer Research... and other collaboratorsActive, not recruitingCervical CancerCanada, France, Austria, Germany, Belgium, United Kingdom, Netherlands, China, Ireland, Norway, Russian Federation
-
Japan Clinical Oncology GroupMinistry of Health, Labour and Welfare, JapanCompleted
-
Seoul National University Bundang HospitalRecruitingGastric Cancer | Gastric AdenocarcinomaKorea, Republic of
-
Shanghai Zhongshan HospitalNot yet recruiting
-
Institut du Cancer de Montpellier - Val d'AurelleCompletedBreast CancerFrance
-
Fujian Medical UniversityUnknown